The standard of care in the treatment of chronic lung disease includes pulmonary rehabilitation (PR). While evidence of the effectiveness of PR in chronic obstructive lung disease (COPD) is robust, that for pulmonary fibrosis and other non-fibrotic restrictive lung diseases is less extensive. However, PR has been shown to improve functional exercise capacity and health-related quality of life in non-COPD patients, primarily those with interstitial lung diseases. This review examines mechanisms of exercise limitation in non-COPD patients and discusses how they might affect both the application of and outcome measures of PR. We also review the assessment of exercise performance, dyspnea, and quality of life as well as special protocols, safety considerations, and special techniques in PR as applied to patients with pulmonary fibrosis or restrictive lung disease. At present, there are no evidence-based guidelines for PR in non-COPD patients whereas PR is firmly recommended in COPD management. More research is needed to strengthen the evidence for the use of PR in non-COPD patients. Meanwhile, the available data, summarized in this review, support the inclusion of PR in the management of all patients with chronic lung disease including pulmonary fibrosis and restrictive lung disease.
Introduction
Pulmonary rehabilitation (PR) can be defined as a structured program of aerobic exercise training, ideally combined with strength training in patients with chronic pulmonary diseases. A pulmonary rehabilitation program involves not just exercise training but also educational lectures, nutritional interventions, and psychological support. Exercise training should utilize a scientifically based exercise prescription and be coupled to rigorous and clinically meaningful outcome measures. 1 Evidence-based support for pulmonary rehabilitation has grown considerably in recent years and demonstrates improvements in dyspnea, exercise performance, and quality of life. 2 The format of a pulmonary rehabilitation program should be adaptable to the needs of the individual patient. Historically, pulmonary rehabilitation programs have been used for outpatients but they tend to be hospitalbased, catering to more severe patients with attention to physiological monitoring such as oxygenation and cardiac telemetry. However, in future these programs will need to be creatively modified for patients with less severe disease, to include a wider range of health and fitness facilities as well as collaborative self-management. 3 Although most of the evidence in support of pulmonary rehabilitation has been developed in patients with chronic obstructive pulmonary disease (COPD), the most recently published clinical practice guidelines for pulmonary rehabilitation support its application in patients with chronic pulmonary diseases other than COPD, including restrictive lung diseases such as pulmonary fibrosis. 4 This review will focus on the mechanisms of exercise limitation in interstitial lung disease (ILD), current evidence for PR in ILD, and special issues in providing PR to patients with ILD.
Mechanisms of exercise limitation
The typical clinical features of interstitial lung disease (ILD) include exertional desaturation and a nonproductive cough. Patients with ILD have significantly reduced exercise capacity as manifested by a reduced maximum work load achieved during exercise, as well as a reduced maximal oxygen uptake (VO 2max ). 5 Reviews on the mechanisms of exercise limitation in patients with interstitial lung diseases highlight a combination of factors including mechanical constraints, ventilatory limitation, gas exchange abnormalities, diffusion limitation, circulatory limitation, abnormalities in muscle oxygen extraction or utilization, alterations in respiratory drive, abnormal breathing patterns, and dynamic hypoinflation during exertion. 6, 7 A small amount of data exists, which describes skeletal muscle weakness in limiting exercise before and after lung transplantation in patients with ILD as discussed below.
Resting pulmonary function testing of patients with ILD demonstrates characteristic alterations. Patients exhibit reductions in lung volumes, static and dynamic lung compliance, and diffusing capacity (D L CO). In addition, they show increased elastic recoil at functional residual capacity and increased expiratory flow in the effort-independent portion of the expiratory flow loop. Reduced flow rates in relation to transpulmonary pressure suggestive of coexisting obstructive airway disease have been reported. 8, 9 A reduction in maximal oxygen uptake is typical during exercise. 5 Unfortunately, pulmonary function testing neither excludes nor quantifies the extent of exercise limitation 10, 11 since resting PFTs do not predict exercise capacity and/or mechanisms of exercise limitation very well. In one study, 14% of patients with various types of ILD demonstrated normal resting pulmonary function studies but abnormal exercise studies. 6 Parameters of resting pulmonary physiology that have been shown to correlate with maximal oxygen uptake include vital capacity (VC; % predicted), forced expiratory volume in 1 sec (FEV 1 ; % predicted), total lung capacity (TLC; % predicted), D L CO (% predicted), and arterial partial pressure of oxygen (PaO 2 ). 6, 12 Whether or not ventilatory limitation is the primary factor limiting exercise remains unresolved.
During exercise, patients with ILD typically exhibit a rapid, shallow breathing pattern due to reduced lung compliance and preferentially increased respiratory frequency rather than tidal volume, 12 the opposite of normal subjects. In a study that utilized exercise tidal flow-volume curves, patients with ILD demonstrated a 67% mean ratio of maximal minute ventilation (V Emax ) to maximal ventilatory capacity indicating that the patients were not breathing near their maximum ventilatory capacity. 6 In addition, ILD patients have been reported to show an inverse correlation between maximum oxygen uptake (VO 2max ) and ventilatory reserve, 6 the opposite of what would be expected if ventilatory mechanics were limiting. However, in nearly half of those subjects, the V Emax was either greater than 85% or within 15 L/min of maximum voluntary ventilation, which suggests ventilatory limitation. Harris-Eze et al. 13 compared the exercise responses of ILD patients exercising while breathing room air versus while breathing supplemental oxygen (60% F I O 2 ) with added external dead space to prevent the fall in minute ventilation. At baseline, the patients were not hypoxemic at rest but exhibited exertional desaturation. The study found the patients were able to increase both peak ventilation and exercise performance with the oxygen and added dead space. The authors concluded that arterial hypoxemia, not respiratory mechanics, limited exercise. The disparate findings across different studies regarding ventilatory limitation perhaps relates to an heterogeneous disease distribution and varying degrees of disease in the patient populations.
During exercise, patients with ILD demonstrate abnormal gas-exchange responses with falls in arterial oxygenation and an abnormal widening of the alveolararterial oxygen gradient (P(A-a)O 2 ). Ventilationperfusion (V A /Q) mismatching accounts for the majority of hypoxemia during rest and exercise, rather than a limitation of oxygen diffusion. Using the technique of multiple inert gas elimination, Agusti et al. 14 showed that in patients with idiopathic pulmonary fibrosis (IPF), 81% of the P(A-a)O 2 was due to V A / Q mismatch and 19% was due to O 2 diffusion limitation. Hansen and Wasserman 6 reviewed the exercise studies in a group of 42 patients with ILD without musculoskeletal disease, obstructive disease, other restrictive disease, or cardiovascular disease. As expected, peak exercise PaO 2 correlated inversely with peak exercise P(A-a)O 2 (r ¼ -0.964) illustrating a gas exchange abnormality characterized by low V A / Q mismatch. In addition, peak exercise PaO 2 correlated with the end-exercise ratio of dead space to tidal volume (V D /V T ; r ¼ 0.909) illustrating a gas exchange abnormality characterized by high V A /Q mismatch. These investigators found that 65% of patients exhibited both high and low V A /Q mismatch and found a stronger association between VO 2max and indices of high V A /Q (increased dead space) rather than low V A /Q mismatch.
A reduction in D L CO is a hallmark of ILD. Among the parameters of resting pulmonary physiology, D L CO has been shown to be the best correlate of VO 2max in ILD. 6 Both D L CO and D L /V A correlate significantly with the increase in the P(A-a)O 2 during exercise in patients with IPF. 15 Pulmonary capillary blood volume is a major contributing factor in the measurement of D L CO and when the D L CO is less than 50% of predicted, pulmonary hypertension and an abnormally widened P(A-a)O 2 can be anticipated during exercise. 14 In the early stages of ILD, pulmonary hypertension occurs during exercise and may not be evident at rest. The degree of elevation of pulmonary arterial pressure during exercise correlates with the severity of arterial hypoxemia. Supplemental oxygen during exercise reverses the hypoxemia and relieves hypoxic pulmonary vasoconstriction but produces only a small reduction in pulmonary arterial pressures due to a passive decrease in cardiac output. 16 Moreover, circulatory dysfunction correlates with impaired oxygen transport. The degree of circulatory dysfunction has been shown to be proportional to the severity of underlying lung disease in terms of loss of lung volume, reduction in the gas transfer, arterial hypoxemia, and to increased dead space with significant reductions in the VO 2max and end-exercise
Patients with ILD are also prone to deconditioning. This physical deconditioning may be due to multiple factors. Patients with ILD suffer from dyspnea and fatigue, leading to a vicious cycle of physical inactivity and worsening symptoms. Quality of life also suffers as discussed below. One reason for dyspnea may be a higher respiratory drive during exercise attributed to increased afferent reflexes originating from the lung and/or the chest wall. 17 Another factor involves the timing of breathing during exercise. Burdon et al. 12 studied a group of ILD patients and found an overall reduction in the total force generated by the respiratory muscles over a given time, i.e. breathing frequency, enabling the muscles to maintain force development without fatigue. With exercise, ILD patients may not have enough time for inspiration, leading to dynamic hypoinflation. As breathing frequency rises and total breath time decreases, the end-inspiratory lung volume falls near end-exercise, the opposite of normal subjects 7, 9 and distinct from COPD patients who develop dynamic hyperinflation with a rise in both end-inspiratory and endexpiratory volumes. 18 Although not proven, it is possible that hypoinflation may contribute to worsened V A /Q mismatch and exaggerate oxygen desaturation during exercise. The breathing patterns of patients with obstructive and restrictive ventilatory disorders differ significantly during exercise, as assessed by the timing ratio of inspiration to expiration, the flow ratio of inspiratory flow to expiratory flow, the timing components of expiratory time, as well as the ratio of inspiratory time to total breath time. 19 These special characteristics explain why patients with ILD develop exertional dyspnea and may affect how they respond to traditional pulmonary rehabilitation designed for COPD patients.
Patients with chronic lung disease demonstrate skeletal muscle abnormalities that contribute to reduced exercise capacity and dyspnea. A body of literature exists for COPD patients and has been recently reviewed. 20, 21 As reviewed, peripheral muscle dysfunction results from inactivity-induced deconditioning, systemic inflammation, oxidative stress, blood gas disturbances, corticosteroid use, and reductions in muscle mass. Similar research for ILD patients is less extensive. In patients with IPF, quadriceps weakness has been shown to be related to exercise limitation (reduced VO 2max ) and lung function impairment (reduced VC). 22 Exercise intolerance is due to leg fatigue as well as dyspnea. The structural and functional disturbances leading to quadriceps weakness in IPF have not yet been studied. The muscles of patients with idiopathic forms of ILD may exhibit changes similar to those seen in COPD, but the literature is lacking. By contrast, sarcoidosis causes ILD and this systemic granulomatous disease may involve the skeletal muscles. As a measure of respiratory muscle strength, both maximal inspiratory and expiratory mouth pressures have been shown to be reduced in sarcoid patients [23] [24] [25] and both are inversely correlated with dyspnea level and forced vital capacity (FVC). 24 Spruit et al. 25 studied sarcoid patients with complaints of fatigue and found they exhibit peripheral muscle weakness as demonstrated by reductions in quadriceps muscle peak torque. These authors suggested that skeletal muscle weakness may be related to corticosteroid-induced myopathy, acute myositis, sarcoid granulomas, or deconditioning while acknowledging that steroid treatment may also improve sarcoid muscle granulomatous involvement.
Of interest is the finding that after lung transplantation (LTx), patients still experience exercise limitation despite (near) normal lung function, which may be explained by skeletal muscle dysfunction. The lung transplant literature reports the results of cohorts of mixed diseases with or without patients with ILD. We are unaware of studies that exclusively report ILD patients. Several studies of patients with chronic lung diseases have confirmed abnormalities in skeletal muscle after LTx. In a mixed study including IPF patients, cardiopulmonary exercise tests with nearinfrared spectroscopy found that exercise limitation was associated with defective peripheral oxygen utilization, suggesting a mitochondrial myopathy. 26 When compared to controls, another mixed study with one IPF patient found reduced type 1 muscle fibers proportion and severely reduced mitochondrial oxidative capacity after LTx. 27 Peripheral muscle weakness as measured by ankle dorsiflexor muscle strength has been shown to be decreased in stable LTx recipients including patients with IPF. 28 Another mixed study that included IPF patients showed that maximal exercise capacity after LTx was reduced due to peripheral muscle limitation in all recipients despite (near) normal lung function. 29 Compared to pre-LTx, the post-LTx values for quadriceps muscle force was significantly reduced and there occurred an early and pathologic lactate threshold. The patients showed no ventilatory limitation during exercise testing after LTx. Similar findings were recently reported in another mixed study including ILD patients. 30 After LTx, the abnormally low baseline quadriceps muscle force significantly decreased. The investigators found that the number of days spent in the intensive care unit after surgery correlated with the decrease in muscle force. Interestingly, exercise training in a PR program did not return the muscle weakness to pre-LTx values, let alone approach near normal. These studies show that patients with ILD after LTx experience ongoing exercise limitation at least in part due to skeletal muscle weakness that likely was also present in the pretransplantation stage of illness.
Collectively, the data discussed in this section suggest that skeletal muscle dysfunction may be an important contributor to exercise limitation for patients with interstitial lung diseases. Importantly, skeletal muscle dysfunction associated with interstitial lung disease is potentially amenable to stabilization and/or improvement in pulmonary rehabilitation. Further research is needed in this important area.
Current evidence for pulmonary rehabilitation for patients with interstitial lung disease
As noted in the introduction, the standard of care for the treatment of chronic lung diseases now includes pulmonary rehabilitation (PR) with the expectation of improving dyspnea, exercise performance, and health-related quality of life. 4, 31 Scientific evidence is relatively sparse in patients with diseases other than COPD and limited data exist specifically addressing the efficacy of pulmonary rehabilitation in patients with pulmonary fibrosis. This section will review existing recommendations in as much as they pertain to patients with pulmonary fibrosis.
Given the extensive literature and accepted efficacy of PR in COPD patients, outcome studies of non-COPD patients typically compare results to those in patients with COPD. However, problems exist in this approach. For instance, studies of non-COPD patients typically include multiple restrictive disorders that are heterogeneous in pathophysiology. For example, an early article reported 32 non-COPD patients of whom only seven had pulmonary fibrosis. 32 The other patients included seven with bronchiectasis, three with fibrothorax, four with scoliosis, four with neuromuscular diseases, and four with other conditions. The mechanisms of exercise limitation for all these types of patients may be fundamentally different. As a whole, this uncontrolled trial of an inpatient PR program of average length of 4 weeks found ambulation distance significantly improved (p < 0.0001) for the non-COPD patients and the improvement was similar to 317 patients with COPD. The differences between the non-COPD groups were not significant by analysis of variance but the pulmonary fibrosis group was in the lower half the groups by order of improvement.
Another problem in analyzing outcomes is the differences in program content at different PR locations. 33 Thus, some reports have suggested efficacy of PR for non-COPD patients but the results of initial studies were not conclusive. One uncontrolled study reported that PR was effective for pulmonary fibrosis 34 but the authors could not completely evaluate the effect of the PR due to the severity of the illnesses and the poor exercise tolerance of the patients. Another study described the outcomes of PR for patients with non-obstructive lung disease (NLD) compared to COPD patients. 35 Neither was the type of NLD patient described nor was a statistical analysis applied to the outcome data. Nevertheless, both COPD and NLD patients demonstrated somewhat similar improvements in physiological and psychological measurements.
In 2000, the American Thoracic Society published a consensus statement regarding IPF. 36 At that time, the guidelines recommended PR but did not provide any scientific evidence to support its efficacy. Subsequently, there has been reported an uncontrolled study reporting benefits. 37 These authors studied 46 patients with restrictive lung disease (35 ILD, 11 skeletal abnormalities) who were admitted to a PR program. The patients exhibited both physiological benefits as well as significant improvement in dyspnea and quality of life. Finally, a retrospective analysis compared the results of 8 weeks of outpatient PR in patients with and without COPD. 38 The non-COPD group of 113 patients (compared to 309 with COPD) included 42 with a variety of interstitial lung diseases, of whom 25 had pulmonary fibrosis. Overall, the non-COPD group showed a significant improvement in both functional exercise capacity measured by 6-min walking distance (p < 0.0001) and quality of life measured by the Chronic Respiratory Disease Questionnaire (p < 0.0001).
The revised joint consensus statement from the American College of Chest Physicians and the American Association of Cardiovascular and Pulmonary Rehabilitation on evidence-based guidelines for PR was published in 2007. 4 The authors gave a 1B recommendation for PR as beneficial for patients with some chronic respiratory diseases other than COPD. Grade 1B equates to a strong recommendation with evidence that benefits of moderate strength outweigh any risks. However, these organizations did not define which non-COPD diseases would appear to benefit.
Recently, the first randomized, single-blinded controlled trial was published in which Holland et al. 39 randomized only ILD patients (57 total, of which 34 had IPF) to undergo either a supervised exercise program similar to that used for COPD or to receive weekly telephone support. The investigators assessed the patients at baseline, after the PR, and at 6 months using 6-min walking distance (dw6), an incremental exercise test, the Medical Research Council (MRC) dyspnea score, the Medical Outcomes Study Short Form 36 (SF-36), and the Chronic Respiratory Disease Questionnaire (CRDQ). In the control group, the mean age was 67 years, the mean FVC was 75% predicted, and the mean D L CO was 49% predicted. The corresponding values for the exercise group were 70 years, 77% predicted, and 50% predicted. Overall, the ILD patients improved after PR compared to controls but had a smaller magnitude of gains compared with those reported in COPD. The dw6 increased by 35 m for the ILD group as a whole. Subgroup analysis showed that the mean improvement for IPF was 25.1 (54.2) m compared to 43.5 (34.2) m for the patients without IPF. Unlike for COPD, 40 the minimal clinically important difference in dw6 for patients with ILD has not been defined. No benefit was shown in the incremental exercise test by measurements of maximum oxygen uptake but there was a lower heart rate at maximum workload. This finding suggested to the authors that the ILD patients had a cardiovascular adaptation. As such, they proposed that maximum exercise capacity is constrained by the pathophysiology of ILD but that submaximal exercise capacity is amenable to training. In addition, measures of quality of life improved as demonstrated by a reduction in dyspnea and fatigue. Overall, the study provides evidence that PR improved walking distance and dyspnea when associated with a reduced functional capacity in ILD patients but unfortunately, these gains were not maintained at 6 months.
Similar results were found in another study published by Nishiyama et al. 22 in which a group of 30 patients with ILD were randomly assigned to undergo PR or to routine medical care. The investigators measured pulmonary function, blood gas analysis, dw6, baseline dyspnea index (BDI), and health-related quality of life (HRQL) score on the St. George's Respiratory Questionnaire (SGRQ) at baseline and after the rehabilitation program. In the control group, the mean age was 64.5 years, the mean FVC was 68.7% predicted, and the mean D L CO was 48.6% predicted. For the rehabilitation group, the corresponding values were 68.1 years, 66.1% predicted, and 59.4% predicted. At the end of the study, those undergoing rehabilitation demonstrated statistically significant improvements in the dw6 (p < 0.05) and the total HRQL score (p < 0.05). Pulmonary function, blood gas analysis, and BDI were not affected. This study did not look for sustained improvement over time.
Both of these recent studies provide evidence that PR improves functional exercise capacity and HRQL in patients with IPF.
The largest study of PR in ILD was recently reported. 38 Of the 99 total patients, 50 had IPF, 42 an unspecified ILD, 3 scleroderma, 2 nonspecific interstitial pneumonia, 1 sarcoidosis, and 1 lymphangioleiomyomatosis. The mean age of the patients was 66 years, 55% were men, only 41% never smoked, with a mean FVC of 62% predicted and mean D L CO of 40% predicted. After a PR of two to three sessions per week for >6-8 weeks (at three centers), the Borg score decreased by an average of 1 unit (p < 0.0001) and 50% of the patients decreased their Borg score by the established minimally clinically significant difference of 1 unit (p < 0.0001). The dw6 increased by an average of 56 m (p < 0.0001) and 49% of the patients increased their dw6 by the established minimal clinically important difference of 54 m (p < 0.0001). The benefits were seen regardless of age, baseline pulmonary function, or the PR center. The authors found that a lower baseline dw6 was associated with lower baseline FVC, D L CO, and the use of longterm oxygen therapy. The findings suggest that even those patients who are severely impaired can substantially improve their functional status with PR. The improvement in dw6 was less pronounced in patients with better baseline values. It is unknown whether improving dyspnea and dw6 prolongs survival or improves outcomes of lung transplantation. Future studies are needed to investigate the optimal timing of PR over the course of the disease and whether some patient subgroups may benefit compared to others, e.g. at differing stages of disease.
Issues in providing pulmonary rehabilitation for patients with ILD Assessment of exercise performance in ILD and exercise prescription
Successful endurance training should achieve clinically meaningful differences that can be objectively measured. As a means for evaluation, cardiopulmonary exercise testing demonstrates the mechanisms of exercise limitation for patients with ILD. For instance, the test may identify those patients with or without ventilatory limitation, deconditioning, and unappreciated cardiovascular limitation. This in turn has potential impact on the formulation of the exercise prescription. From the patient's perspective, meaningful improvements relate to functional exercise capacity and quality of life. In most PR programs, functional exercise testing is preferred to formal exercise testing from the practical standpoint, due to the simplicity of the former and its relevance to activities of daily living. For the COPD patient, the 6-min walking test has become a standard and reproducible test 41 with published reference values. 42 A simplified calculation for normal dw6 is as follows:
where dw6 is the 6-min walking distance in meters and age is in years. 43 The clinically meaningful difference in 6-min walking distance has been determined for COPD patients. In a study of 112 patients with stable COPD, a change of 54 m was found to be the smallest difference in patients' subjective comparison ratings of their walking ability. 40 Another study performed a meta-analysis of pulmonary rehabilitation studies in COPD and found that an average increase of 56 m was associated with perceived benefit in dyspnea by the patients. 44 A more recent publication has suggested that the minimum clinically important difference of 35 m is more appropriate in patients with severe COPD and mean forced expiratory volume in 1 second (FEV 1 ) of 39%. 45 The minimally clinically significant improvement in the dw6 test has yet to be established in patients with pulmonary fibrosis but it is reasonable to assume that the same principles apply to these patients as to patients with COPD and the same minimal clinically important difference can be adopted until further information becomes available.
An early study of a mixed group of non-COPD patients reported changes in dw6 after PR. 32 In this heterogeneous group of 32 patients that included 7 with pulmonary fibrosis, dw6 increased from 276 + 219 ft (SD) to 574 + 367 ft (p < 0.0001). The authors stated the improvement did not differ from previously reported data in COPD patients. Recently, a study was published that evaluated the effects of PR on exercise capacity in 57 patients with ILD, 34 of whom had IPF. 39 After PR, the dw6 improved by 35 m and there was no difference between the IPF patients and the other ILD. Interestingly, the patients achieved no improvement in peak oxygen uptake (VO 2 ) but did demonstrate a reduction in heart rate at maximal workload. This finding implied a cardiovascular adaptation suggesting that maximum exercise capacity is constrained by the pathophysiology of ILD but that submaximal exercise capacity may be amenable to exercise training. In another recent study, the authors evaluated the reproducibility of the 6-min walk test and maximal exercise in 30 consecutive patients with fibrotic IPF at an interval of 1 week. 46 They found excellent within-subject reproducibility for the dw6 (r ¼ 0.98 and SD/mean ¼ 4.2%) and a highly significant relationship between maximum VO 2 on maximal exercise testing and the dw6 (r ¼ .78, p < 0.0001). These findings have been used to support the role of dw6 in routine staging and monitoring of patients with pulmonary fibrosis.
One interesting study published recently evaluated dyspnea during 6-min walking tests in IPF compared to COPD. 47 The authors studied 41 patients with IPF and 41 age-matched and resting PaO 2 value-matched COPD patients. They found that O 2 saturation at the end of the test was an independent predictor of dyspnea in IPF (r 2 ¼ 0.27, p < 0.0005), whereas FEV 1 was the only predictor in COPD (r 2 ¼ 0.16, p < 0.0096). The IPF patients exhibited more desaturation (to a low of 83.6% + 9.1% in IPF versus 88.0% + 5.9% in COPD, p < 0.001) but rated less dyspnea by Borg Scale (3.6 + 2.1 in IPF versus 4.6 + 1.9 in COPD, p < 0.05). These findings highlight differences in the pathophysiology of dyspnea between COPD and non-COPD patients and how these differences may affect the choice of an exercise assessment tool.
Assessment of dyspnea and quality of life in ILD
Unlike for COPD, limited research has been conducted on how pulmonary fibrosis impacts living with the disease, also termed health-related quality of life (HRQL). There exist multiple validated tools to assess these parameters in COPD patients. 48 To date, no disease-specific instrument has been created to measure HRQL in patients with IPF 49 but the COPD tools have been studied in ILD patient population. 50 Swigris et al. 50 recently published a systematic review of published literature on HRQL in patients with IPF. Only seven studies met inclusion criteria that measured HRQL in at least 10 patients with IPF. None measured longitudinal changes in HRQL. Patients with IPF demonstrated substantially impaired HRQL in domains that measure physical health and level of independence and the findings were similar to those in patients with COPD. In addition, measures of dyspnea correlated moderately well with scores from domains that measure physical health and energy/fatigue/pep. However, measures of pulmonary function and gas exchange were not found to correlate with HRQL. This finding suggested to the authors that the variability in HRQL is only partially explained by measures of dyspnea or pulmonary function and that HRQL measures provide unique information for this patient population. They suggested that more research needs to be conducted to identify and design appropriate measurement instruments in patients with IPF as well as to study changes over time.
Over the last several years, various studies have applied one or more health status assessment tools to patients with IPF even though they are not specific for this disease. A study by De Vries et al. 51 suggested that the SF-36 was effective for measuring general health status but the WHOQOL-100 was better for individual patient opinions. Dyspnea has been found to be the most important factor affecting quality of life as measured by the SF-36 in patients with IPF. 52 Similarly, subjective breathlessness is related to quality of life and depressive symptoms as measured by WHOQOL-100 and BDI, respectively. 51 Tzanakis et al. 53 asked 25 patients with IPF and 30 controls to complete 3 dyspnea scales (Borg, OCD, and a modified MRC) and HRQL questionnaires (SGRQ, QWB, HAD). They found that lung volumes (FVC and TLC) correlated with the SGRQ and that the D L CO and blood oxygenation at rest and during exercise correlated with all dyspnea scales. In a study of 50 patients with ILD, Chang et al. 54 administered four HRQL measurements. Scores from all questionnaires correlated significantly with dw6 and dyspnea scores. They also found that scores from the SF-36, QWB, and SGRQ significantly correlated with FVC, FEV 1 , and D L CO. In particular, the SF-36 and SGRQ were found to be good measures of health status but the QWB content and scaling were found to be incapable of distinguishing between patients with varying degrees of IPF severity. Another study applied the SGRQ to 41 patients with IPF. 22 The total SGRQ score correlated with total lung capacity, D L CO, arterial partial pressure of oxygen at rest, lowest oxygen saturation with exercise, and baseline dyspnea index but did not correlate with peak oxygen uptake or VC. This study included patients with mild-to-moderate lung impairment (VC 76.6% + 16.8%) so the lack of correlation with VC may not apply to patients with more advanced disease. Interestingly, the peak VO 2 did not correlate with SGRQ scores whereas resting PaO 2 did, which is opposite to what has been described in COPD patients. 55 Again, these findings underscore the differences in the mechanisms of dyspnea in COPD compared to non-COPD patients and the need to develop disease-specific health status measurement tools for patients with ILD and other restrictive disorders.
Aiming to develop disease-specific assessment tools for IPF, Swigris et al. 56 conducted a study using focus groups as well as in-depth interviews with 20 patients with IPF. They analyzed patient perspectives and organized them into a conceptual framework for describing HRQL in this disease. The authors identified 12 primary domains: symptoms, IPF therapy, sleep, exhaustion, forethought, employment and finances, dependence, family, sexual relations, social participation, mental and spiritual well-being, and mortality. They also compared the content of this conceptual framework to existing instruments (WHOQOL-100, SF-36, CRQ, and SGRQ) and found them to be inadequate for patients with IPF. They concluded that existing tools do not assess all that IPF patients find to be important.
Patient-centered outcome measures in the rehabilitation of patients with ILD
Outcomes research presupposes the existence of effective treatment. To date, no pharmacologic treatment (with the exception of supplemental oxygen) has been shown to be effective at relieving dyspnea in IPF. By contrast, there is reasonable evidence that PR can improve important patient-centered outcomes including dyspnea for COPD and non-COPD patients including IPF. As described above, there are many HRQL tools but none specifically designed for diseases other than COPD. Even so, several studies published recently have adopted various dyspnea and HRQL scales in order to validate outcome data in patients with ILD after participation in a pulmonary rehabilitation program.
Two uncontrolled studies published in 2006 enrolled 46 patients with restrictive disease and 31 patients with interstitial lung diseases into a PR program. 37, 57 The latter study included 35 patients with ILD and 11 with skeletal deformities. Jastrzebski et al. 57 administered four dyspnea scales (MRC, OCD, BDI, and Borg) and two HRQL tools (SF-36, SGRQ) whereas Naji et al. 37 utilized only the Borg score for dyspnea and the CRDQ and SGRQ for HRQL adding the HAD. In the former study, the patients demonstrated a significant decrease in dyspnea only in the Borg scale (3.0 + 1.4 before vs 2.5 + 1.4 after, p < 0.01) and only some domains of quality of life improved (Role-Physical in the SR-36; activity, impact, and total in the SGRQ). In the latter study, patients showed a statistically significant difference in the dyspnea component of the CRDQ scale as well as overall scores for the CRDQ and SGRQ and the depression portion of the HAD. Combined, these two studies lend support to the value of PR in ILD.
Only recently, the first controlled studies of PR in ILD were published. 22, 39 As previously discussed, the control groups in these studies were not described in any detail. In the Holland study, 39 dyspnea scores improved as measured by the modified MRC dyspnea score and the CRDQ dyspnea domain and HRQL improved only in the fatigue domain of the CRDQ and the vitality domain of the SF-36. Unfortunately, these benefits seemed to be lost after 6 months. This important observation is consistent with findings in COPD that benefits of pulmonary rehabilitation, including functional exercise capacity and quality of life, diminish over time without a maintenance exercise program. 58, 59 The study by Nishiyama et al. 22 found limited improvement in the total SGRQ score (p < 0.05) but neither the symptom domain of the SGRQ nor the dyspnea score improved. We eagerly await the results of larger trials, especially if disease-specific HRQL tools are developed.
Special protocol and safety considerations in exercise training
Like patients with COPD, patients with other lung diseases typically have fixed or only partially reversible abnormalities of respiratory system mechanics. Both COPD and non-COPD patients may experience exercise intolerance but for reasons of different underlying pathophysiology. These differences need to be addressed in PR programs for non-COPD participants. At present, there are no evidence-based guidelines for PR in patients with chronic lung diseases other than COPD. 20 As such, expert opinion suggests exercise training should include a combination of aerobic and strength training of the upper and lower extremity muscles. The PR staff should be trained in understanding the wide range of physiologic abnormalities in the non-COPD chronic lung diseases and direct the exercise prescription taking into consideration individual patient safety concerns and goals. For instance, patients with pulmonary fibrosis may experience severe dyspnea and exertional desaturation that is difficult to overcome with supplemental oxygen. The PR staff may need to manage a transtracheal oxygen catheter in patients with refractory hypoxemia. Improving nutritional deficiencies as well as peripheral skeletal and respiratory muscle weakness may be a goal in patients awaiting surgery such as lung transplantation. Special equipment may be required to accommodate patients with high oxygen requirements or arm exercise equipment may be required in patients with marked quadriceps weakness.
Of special concern is the patient with secondary pulmonary hypertension, a complication of pulmonary fibrosis and many other chronic lung diseases, both COPD and non-COPD. Severe pulmonary hypertension had been considered a contraindication to participate in PR, but with attention to the nature and intensity of exercise, these patients may be enrolled in an exercise program. 20 Persons with pulmonary hypertension participating in PR are optimally monitored by telemetry if available, especially if they are known to have experienced cardiac dysrhythmias. All patients should have blood pressure and heart rate monitored during exercise. Activities that increase intrathoracic pressure such as resistance exercise or high-intensity aerobic exercise should be avoided as they may lead to circulatory collapse and syncope. Special attention should be paid to the cool-down or recovery period following exercise since rapid falls in cardiac output can lead to syncope in patients with pulmonary hypertension. The exercise intensity should be reduced somewhat gradually and cardiac monitoring should continue until hemodynamic measures have returned to baseline. Exercise must be stopped if the patient develops chest pain, lightheadedness, or palpitations. Care must be taken to ensure adequate oxygenation, to avoid interrupting continuous intravenous vasodilator therapy and to avoid falls in patients on anticoagulation medication.
The role of patient and provider education
Pulmonary rehabilitation typically includes patient education. Individualized educational materials would benefit the non-COPD patient in the typical PR program composed mainly of COPD patients. The staff needs to be educated in the pathophysiology, mechanisms of exercise limitation, the natural course, signs of disease destabilization, and therapeutic interventions for patients with ILD and also for all the other non-COPD chronic lung diseases. Pulmonary rehabilitation may also play a role in preparing the patient for lung surgery, including transplantation. Not only may gains be achieved in functional capacity with exercise but PR programs could achieve other goals such as education about the surgery itself, helping the patient's medical and surgical team with perioperative management issues and medications, and providing the patient with a support group.
Special techniques in pulmonary rehabilitation
Pulmonary rehabilitation has been defined as 'an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities.' 20 The traditional PR program for COPD utilizes endurance training and has been shown to improve both exercise endurance as well as health-related quality of life. 31 Other modalities, either combined with or independent of endurance training, have been studied in patients with COPD. 60 These include endurance training with longacting bronchodilators, 61 supplemental oxygen, 62, 63 inspiratory pressure support 64, 65 or nocturnal noninvasive positive pressure ventilation, 66 and respiratory muscle training. 67, 68 In addition to endurance training, other methods have been studied including interval training, 69, 70 resistance or strength training, 71, 72 neuromuscular stimulation, 73, 74 and supplements including oral creatine, 75 anabolic steroids, 76, 77 and polyunsaturated fatty acids. 78 While research experience of rehabilitation techniques in COPD patients is certainly extensive, that for pulmonary diseases other than COPD lags behind. Few, if any, studies have been published to date describing special techniques of PR in patients with ILD.
Expiratory flow limitation at lower lung volumes (such as can occur during exercise) has been described in ILD 79 and the addition of the longacting bronchodilator tiotropium to PR in COPD patients is known to improve endurance time for constant work rate treadmill exercise as well as dyspnea and HRQL measured by SGRQ 61 . To our knowledge, no studies have been published adding a long-acting bronchodilator to PR in ILD patients. The use of supplemental oxygen during PR in COPD patients may also improve exercise intensity and reduce symptoms in the research setting regardless of oxygen desaturation during exercise 63 but improvement in clinical outcome is not well established. 20, 60 For the patient with ILD, provision of supplemental oxygen during cycle exercise improves endurance time at a constant submaximal work load (p < 0.001) compared to exercise breathing room air. 10 On a practical level, PR programs monitor and correct exertional hypoxemia within the constraints of the patient's pathophysiology.
Noninvasive positive pressure ventilation (NIPPV) or inspiratory pressure support reduces dyspnea and improves exercise tolerance in COPD. 20, 65, 66, 80 Also, in COPD patients with reduced respiratory muscle strength, the addition of inspiratory muscle training to PR has been shown to improve exercise capacity compared to exercise training alone. 20, [65] [66] [67] Intervalbased high-intensity inspiratory muscle training in COPD improves inspiratory muscle function, exercise capacity, and HRQL measured by the CRDQ. 81 However, another study failed to demonstrate functional improvement in either quality of life (CRDQ) or exercise performance (peak exercise capacity, exercise endurance time, and dw6) when combining respiratory muscle endurance training with PR despite increasing mean respiratory muscle endurance (p ¼ 0.02). 68 Expiratory muscle training in COPD patients improves exercise capacity (cycle ergometry and walking test) as well as dyspnea and quality of life (SGRQ) but not lung function. 68 By contrast, similar data for pulmonary fibrosis patients is lacking. The addition of respiratory muscle training or positive pressure support with exercise training in ILD patients remains to be studied. One study attempted to assess the efficacy of home NIPPV in 80 patients with chronic hypercapnic respiratory failure due to post-tuberculous fibrosis, kyphoscoliosis, COPD, bronchiectesis, and interstitial pneumonia. 82 Most of the patients with interstitial pneumonia died within 3 months, suggesting that hypercapnea represents a terminal stage although it is not clear if daytime exercise tolerance was evaluated in the study.
Moreover, alternatives to traditional exercise endurance training have been reported for COPD but not for ILD patients. Interval training has been shown to improve HRQL and exercise capacity in patients with moderate-to-severe COPD, 70,83 especially those with dynamic hyperinflation. 69 Strength training targets specific muscle groups by repetitive lifting of weights or muscle contraction against calibrated resistance from a weight machine. This type of exercise places a small demand on the respiratory system with a lower sensation of dyspnea than endurance exercise 83 and leads to gains in upper and lower body muscle strength 84 but results in no significant improvement in functional exercise capacity, quadriceps muscle fatigability, or health status. 71, 86 Neuromuscular electrical stimulation (NMES) attempts to elicit beneficial training effects by the passive stimulation of contraction of the peripheral muscles. In COPD patients with marked peripheral muscle weakness, benefits have been reported with NMES improving muscle strength and exercise capacity 73 as well as allowing severe cases to be able to participate in PR. 74 The addition of oral supplements to the PR intervention variably improves some but not all outcome measures. Oral creatine enhances muscle mass and function during exercise training but has not led to an improvement in exercise capacity in moderate-tosevere COPD patients. 75 In men with low testosterone levels and COPD, anabolic steroids have been shown to improve lean body mass and leg muscle strength similar to leg resistance training, and the results are additive. 76 Lastly, polyunsaturated fatty acids added to PR in patients with moderate to severe COPD improve fat-free muscle mass and skeletal muscle function enhancing exercise capacity more than PR alone. 78 None of these approaches discussed above has yet been studied in ILD patients.
Conclusion
Pulmonary rehabilitation is of proven benefit in patients with COPD and is likely to yield similar improvements in patients with ILD. This article has reviewed the specific physiological limitations to exercise performance in ILD and evaluated the evidence of improvements in patient-centered outcomes with interventions such as structured exercise training, supplemental oxygen, pharmacotherapy, and patient education. More research needs to be focused in this area to strengthen the evidence but in the meantime, it seems logical to utilize the techniques described in existing COPD clinical practice guidelines for patients with ILD.
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